<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-five patients with advanced <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> (ET; n = 13) or <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>; n = 12) received hemopoietic stem cell transplants (HSCT) at the Fred Hutchinson <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Research Center </plain></SENT>
<SENT sid="1" pm="."><plain>In most cases the indication to perform an HSCT was <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> with <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> and peripheral blood cytopenias or the development of a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were 18-60 (median 43) years old with intervals from diagnosis to HSCT of 8-348 (median 168) months </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> but five patients had been treated with cytotoxic agents, and nine patients were splenectomized before transplant </plain></SENT>
<SENT sid="4" pm="."><plain>Conditioning was performed with chemotherapy only or chemotherapy plus total body irradiation regimens followed by the infusion of either marrow (n = 19) or peripheral blood stem cells (n = 6) from related (n = 16) or unrelated (n = 9) donors </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> evaluable patients showed sustained neutrophil engraftment </plain></SENT>
<SENT sid="6" pm="."><plain>Nine patients (seven with <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e>, two with <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo>) died of transplant-related complications, and 16 are surviving, 14 of them in continuous unmaintained remission </plain></SENT>
<SENT sid="7" pm="."><plain>With a median follow-up of 41 (range 5-116) months after transplant, survival at 3 years is 64% </plain></SENT>
<SENT sid="8" pm="."><plain>These data provide evidence that HSCT can be a curative treatment for patients with advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> and ET </plain></SENT>
</text></document>